Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in VHL Disease-Associated Renal Cell Carcinoma
NCT03401788Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2018
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of belzutifan in von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC), sponsored by Merck & Co.. Started May 2018; status: active, not recruiting.
02
Drugs
belzutifan
03
Conditions
von Hippel-Lindau disease-associated renal cell carcinoma (VHL-RCC)
Beyond the preview
Go deeper on NCT03401788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401788.